Global Angiogenesis Modulators Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Angiogenesis Modulators Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Angiogenesis Modulators report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Angiogenesis Modulators market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Breast Cancer and Colorectal Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Angiogenesis Modulators industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Angiogenesis Modulators key manufacturers include Celgene Corporation (USA), Eisai (Japan), Amgen, Inc. (USA), Genentech, Inc. (USA), GlaxoSmithKline plc (UK), Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA) and AstraZeneca plc (UK), etc. Celgene Corporation (USA), Eisai (Japan), Amgen, Inc. (USA) are top 3 players and held % sales share in total in 2022.
Angiogenesis Modulators can be divided into Angiogenesis Inhibitors, Angiogenesis Stimulators, Angiogenin and Others, etc. Angiogenesis Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Angiogenesis Modulators is widely used in various fields, such as Breast Cancer, Colorectal Cancer, Lung Cancer and Prostate Cancer, etc. Breast Cancer provides greatest supports to the Angiogenesis Modulators industry development. In 2022, global % sales of Angiogenesis Modulators went into Breast Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiogenesis Modulators market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Celgene Corporation (USA)
Eisai (Japan)
Amgen, Inc. (USA)
Genentech, Inc. (USA)
GlaxoSmithKline plc (UK)
Bayer Pharma AG (Germany)
Bionomics Ltd. (Australia)
CASI Pharmaceuticals, Inc. (USA)
AstraZeneca plc (UK)
Eli Lilly and Company (USA)
F.Hoffmann-La Roche AG (Switzerland)
Segment by Type
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Angiogenesis Modulators market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Angiogenesis Modulators, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Angiogenesis Modulators industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Angiogenesis Modulators in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Angiogenesis Modulators introduction, etc. Angiogenesis Modulators Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Angiogenesis Modulators market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Angiogenesis Modulators industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Angiogenesis Modulators key manufacturers include Celgene Corporation (USA), Eisai (Japan), Amgen, Inc. (USA), Genentech, Inc. (USA), GlaxoSmithKline plc (UK), Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA) and AstraZeneca plc (UK), etc. Celgene Corporation (USA), Eisai (Japan), Amgen, Inc. (USA) are top 3 players and held % sales share in total in 2022.
Angiogenesis Modulators can be divided into Angiogenesis Inhibitors, Angiogenesis Stimulators, Angiogenin and Others, etc. Angiogenesis Inhibitors is the mainstream product in the market, accounting for % sales share globally in 2022.
Angiogenesis Modulators is widely used in various fields, such as Breast Cancer, Colorectal Cancer, Lung Cancer and Prostate Cancer, etc. Breast Cancer provides greatest supports to the Angiogenesis Modulators industry development. In 2022, global % sales of Angiogenesis Modulators went into Breast Cancer filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Angiogenesis Modulators market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Celgene Corporation (USA)
Eisai (Japan)
Amgen, Inc. (USA)
Genentech, Inc. (USA)
GlaxoSmithKline plc (UK)
Bayer Pharma AG (Germany)
Bionomics Ltd. (Australia)
CASI Pharmaceuticals, Inc. (USA)
AstraZeneca plc (UK)
Eli Lilly and Company (USA)
F.Hoffmann-La Roche AG (Switzerland)
Segment by Type
Angiogenesis Inhibitors
Angiogenesis Stimulators
Angiogenin
Others
Segment by Application
Breast Cancer
Colorectal Cancer
Lung Cancer
Prostate Cancer
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Angiogenesis Modulators market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Angiogenesis Modulators, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Angiogenesis Modulators industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Angiogenesis Modulators in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Angiogenesis Modulators introduction, etc. Angiogenesis Modulators Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Angiogenesis Modulators market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices